Rashidi Maryam, Wicks Ian P, Vince James E
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Trends Mol Med. 2020 Nov;26(11):1003-1020. doi: 10.1016/j.molmed.2020.06.005. Epub 2020 Jul 6.
The accumulation of cellular and environmental microparticles has been linked to many diseases associated with tissue inflammation. These particulate-driven diseases include joint, lung, kidney, cardiovascular, and neurodegenerative disorders. Recently a conserved proinflammatory inflammasome signaling pathway elicited by such microparticles has become apparent. Here, we review disease-promoting microparticles and the mechanisms by which they trigger activation of the inflammasome complexes responsible for generating bioactive interleukin-1β (IL-1β) and inducing cell death. We highlight how microparticle-induced inflammasome and cell death responses diverge from canonical inflammasome activators, and discuss the preclinical and clinical targeting of inflammasomes to treat microparticle-driven diseases.
细胞和环境微粒的积累与许多与组织炎症相关的疾病有关。这些由微粒引发的疾病包括关节、肺部、肾脏、心血管和神经退行性疾病。最近，由这类微粒引发的保守的促炎炎性小体信号通路已变得明显。在这里，我们综述了促进疾病的微粒以及它们触发负责产生生物活性白细胞介素-1β（IL-1β）和诱导细胞死亡的炎性小体复合物活化的机制。我们强调了微粒诱导的炎性小体和细胞死亡反应与经典炎性小体激活剂的不同之处，并讨论了针对炎性小体治疗微粒驱动疾病的临床前和临床靶向治疗。
